Icosavax to Participate in the Jefferies London Healthcare Conference
09 November 2023 - 12:00AM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases and a vision
of creating pan-respiratory vaccines for older adults, today
announced that the company will participate in and host one-on-one
meetings at the Jefferies London Healthcare Conference, taking
place from November 14-16, 2023 in London, UK.
Jefferies London Healthcare
Conference
- Adam Simpson,
Chief Executive Officer of Icosavax, will participate in a fireside
chat in London on Wednesday, November 15 at 4:00 pm GMT (11:00 am
ET).
Interested parties can register for and access
the live webcast for this conference by visiting the “Events”
section of the Icosavax website. The webcast replay will be
available after the conclusion of the presentation.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its
innovative VLP platform technology to develop vaccines against
infectious diseases, with an initial focus on life-threatening
respiratory diseases and a vision for combination and
pan-respiratory vaccines. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s lead program is a combination vaccine candidate
targeting respiratory syncytial virus (RSV) and human
metapneumovirus (hMPV), and its pipeline includes additional
programs in influenza and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance
the breakthrough VLP technology from the Institute for Protein
Design at the University of Washington with the goal to discover,
develop, and commercialize vaccines against infectious diseases.
Icosavax is located in Seattle.
For more information, visit www.icosavax.com.
Media Contact:Jessica Yingling, Ph.D.,Little
Dog Communications Inc.jessica@litldog.com858.344.8091
Investor Contact:Laurence WattsGilmartin Group,
LLClaurence@gilmartinir.com619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jul 2023 to Jul 2024